Cardiol Therapeutics is a nanotherapeutics company focusing on research and commercial development of proprietary drug formulations for the treatment of heart failure and cancer. Co. produces pharmaceutical cannabidiol ("CBD") products and develops innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Co.'s lead product, CardiolRx, is designed to be the safest and most consistent CBD formulation on the market. CardiolRx is pharmaceutically produced, cGMP certified, and does not contain any THC. The CRDL stock yearly return is shown above.
The yearly return on the CRDL stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CRDL annual return calculation with any dividends reinvested as applicable (on ex-dates).
|